Latest filing published 02 Oct 2026 for TScan Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -64.7%Entry US$8.63 · Close at T+365 US$3.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Zoran Zdraveski: trading record in brief
Zoran Zdraveski (board member) discloses dealings in 2 companies, chiefly Dianthus Therapeutics, Inc. /DE/ and TScan Therapeutics, Inc. We count 15 filings; the first trade dates from 25 June 2018 and the latest from 1 October 2026.
Market trades split into 1 purchase (€30k) and 5 sales (€1.2M). On balance, insiders were net sellers of €1.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 1 share grant and 7 option exercises.
On 2 October 2026 came the latest disclosure, a share grant in TScan Therapeutics, Inc. The latest purchase dates back some time: it was published 1,869 days ago, on 27 September 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Zoran Zdraveski
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 300,000 shares0Voting Common StockSEC:0001193125-26-412518:0
- 54,895 shares@ US$4.8588.9% of flowVoting Common StockSEC:0000950170-24-101161:0
- 4,716 shares@ US$7.475711.1% of flowVoting Common StockSEC:0000899243-21-037802:0Canonical exit: 22 Dec 2021 (T+90)
3 of 3 declarations
